Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus topotecan in relapsed small-cell lung cancer
NL-OMON42328Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Nivolumab with Topotecan (2 arms). Primary endpoint: Overall survival. Planned start Aug 2015; status: withdrawn.
02
Drugs
nivolumabtopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON42328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42328.